Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Ola Lindén"'
Autor:
Henna‐Riikka Junlén, Kristina Sonnevi, Ola Lindén, Mats Hellström, Mariana Villegas Scivetti, Mikael Olsson, Ida Tufvesson, Ann‐Sofie Johansson, Björn Engelbrekt Wahlin
Publikováno v:
eJHaem, Vol 4, Iss 3, Pp 647-655 (2023)
Abstract The treatment of splenic marginal zone lymphoma is debated: splenectomy (the old standard‐of‐care) is better than chemotherapy but maybe not better than rituximab‐containing treatment. We examined all 358 patients diagnosed with spleni
Externí odkaz:
https://doaj.org/article/14ba6b16f13442de8900e031480884d7
Autor:
Eva Kimby, Birger Christensson, Birgitta Sander, Anne M. Tierens, Martin Maisenhölder, Tuula Lehtinen, Peter de Nully Brown, Christian H. Geisler, Bjørn Østenstad, Marie Nordström, Ola Lindén, Herman Nilsson-Ehle, Martin Erlanson, Hans Hagberg, Harald Holte, Christer Sundström, Björn Engelbrekt Wahlin
Purpose: T cells influence outcome in follicular lymphoma, but their contributions seem to be modified by therapy. Their impact in patients receiving rituximab without chemotherapy is unknown.Experimental Design: Using flow cytometry, we evaluated th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::457bdc64c63055afde578b47747904b0
https://doi.org/10.1158/1078-0432.c.6518275
https://doi.org/10.1158/1078-0432.c.6518275
Autor:
Eva Kimby, Birger Christensson, Birgitta Sander, Anne M. Tierens, Martin Maisenhölder, Tuula Lehtinen, Peter de Nully Brown, Christian H. Geisler, Bjørn Østenstad, Marie Nordström, Ola Lindén, Herman Nilsson-Ehle, Martin Erlanson, Hans Hagberg, Harald Holte, Christer Sundström, Björn Engelbrekt Wahlin
Supplementary Materials and Methods from T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57d9738ab3d939749f3c61331f3f2fbd
https://doi.org/10.1158/1078-0432.22441123.v1
https://doi.org/10.1158/1078-0432.22441123.v1
Publikováno v:
Cancer biotherapyradiopharmaceuticals. 35(7)
Thorium-227 (227Th) is a long-lived (T1/2 = 18.7 d) α-emitter that has emerged as candidate for radioimmunotherapy. Imaging of patients treated with thorium-227 conjugates is challenging due to the...
Autor:
Fred Saad, Ola Lindén, Clemens Kratochwil, Val Lewington, Jae H. Park, Chris Parker, Moshe Yair Levy, Neal D. Shore, Walter Noordzij
Publikováno v:
JAMA Oncology. 4:1765
IMPORTANCE Targeted alpha therapy attempts to deliver systemic radiation selectively to cancer cells while minimizing systemic toxic effects and may lead to additional treatment options for many cancer types. OBSERVATIONS Theoretically, the high-ener
Autor:
Marie Nordström, Eva Kimby, Hans Hagberg, Martin Erlanson, Christer Sundström, Tuula Lehtinen, Bjørn Østenstad, Christian H. Geisler, Birgitta Sander, Herman Nilsson-Ehle, Anne Tierens, Björn E. Wahlin, Peter de Nully Brown, Martin Maisenhölder, Harald Holte, Birger Christensson, Ola Lindén
Publikováno v:
Clinical Cancer Research. 17:4136-4144
Purpose: T cells influence outcome in follicular lymphoma, but their contributions seem to be modified by therapy. Their impact in patients receiving rituximab without chemotherapy is unknown. Experimental Design: Using flow cytometry, we evaluated t
Autor:
Sven-Erik Strand, Karin Wingårdh, David Minarik, Michael Ljungberg, Katarina Sjögreen-Gleisner, Ola Lindén, Jan Tennvall
Publikováno v:
Journal of Nuclear Medicine. 51:1974-1978
This feasibility study demonstrates 90Y quantitative bremsstrahlung imaging of patients undergoing high-dose myeloablative 90Y-ibritumomab treatment. Methods: The study includes pretherapy 111In SPECT/CT and planar whole-body (WB) imaging at 7 d and
Autor:
Robert Foa, Michael Crump, Paula Marlton, H. U. Burger, John F. Seymour, B. Brennan, Ola Lindén, Bertrand Coiffier, F. Morschhauser, E. Wassner, Myriam Mendila, Umberto Vitolo
Publikováno v:
Annals of Oncology. 21:1870-1876
Background: Ocrelizumab is a humanized anti-CD20 antibody with increased antibody-dependent cellular cytotoxicity compared with rituximab. This phase I/II study evaluated its safety and efficacy in patients with relapsed/refractory follicular lymphom
Publikováno v:
Leukemia & lymphoma, 51(Suppl. 1), 20-27. Informa Healthcare
Non-Hodgkin lymphoma (NHL) remains one of the most common cancers in the US, with survival dependent on the type and stage of disease. B-cell lymphomas account for approximately 85% of all cases of NHL, and are commonly treated with chemotherapy, or
Publikováno v:
Artificial Organs; 31(3), pp 208-214 (2007)
The use of monoclonal antibodies (MAbs) in cytotoxic conjugates (radionuclides, toxins, or drugs) for targeting tumor cells is restricted due to toxicity in vital organs. Through improved tumor targeting, it is possible to administer larger amounts o